<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28473813</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-302X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>Frontiers in microbiology</Title><ISOAbbreviation>Front Microbiol</ISOAbbreviation></Journal><ArticleTitle>Asunaprevir Evokes Hepatocytes Innate Immunity to Restrict the Replication of Hepatitis C and Dengue Virus.</ArticleTitle><Pagination><StartPage>668</StartPage><MedlinePgn>668</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">668</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmicb.2017.00668</ELocationID><Abstract><AbstractText>Type I Interferon-mediated innate immunity against <i>Flaviviridae</i>, such as Hepatitis C virus (HCV) and Dengue virus (DENV), involves TLR3, RIG-I-like receptor (RLR) and JAK-STAT signal pathways. Asunaprevir is a newly developed HCV protease inhibitor for HCV treatment. Whether, asunaprevir activates innate immunity to restrict viral infection is unclear. Thus, this study investigates the effect of asunaprevir on innate immunity and its influence on HCV and DENV infection. Huh 7.5.1, Hep-G2 cells, JFH-1 infection model, and DENV-2 infection were used for the analysis. The activity of asunaprevir-regulated innate immunity signal pathway was assessed with IFN-&#x3b2; promoter or IFN-stimulated responsive element (ISRE) reporter assays and immunoblotting of key signal proteins. siRNA-mediated MAVS and TRIF knockdown of cells was performed to assess the effect of asunaprevir-regulated innate immunity against HCV and DENV. Asunaprevir treatment activated ISRE and IFN-&#x3b2; promoter-luciferase activities and signaling proteins in the JAK-STAT, MAVS, and TRIF pathways in Huh 7.5.1 cells. Asunaprevir-mediated signaling activation was decreased in MAVS-knockdown cells. Importantly, both RNA and protein levels of DENV-2 NS3 were decreased in asunaprevir-treated Huh 7.5.1 and HepG2 cells. In MAVS-knockdown cells, the restrictive effect of asunaprevir on HCV and DENV was attenuated. Our findings reveal an unexpected activity of asunaprevir, the activation of MAVS dependent innate immunity to restrict HCV and DENV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Wei-Lun</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General HospitalKaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Yang-Ming UniversityTaipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Jin-Shiung</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General HospitalKaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Yang-Ming UniversityTaipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Chih-Wen</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard UniversityBoston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Kwok-Hung</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General HospitalKaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Yang-Ming UniversityTaipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Hoi-Hung</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General HospitalKaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Yang-Ming UniversityTaipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chun-Ching</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General HospitalKaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jing-Mei</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General HospitalKaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Ping-I</ForeName><Initials>PI</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General HospitalKaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, National Yang-Ming UniversityTaipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Raymond T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Medical Education and Research, Kaohsiung Veterans General HospitalKaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Tsung-Hsien</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard UniversityBoston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, Chung Hwa University of Medical TechnologyTainan, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Microbiol</MedlineTA><NlmUniqueID>101548977</NlmUniqueID><ISSNLinking>1664-302X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dengue virus</Keyword><Keyword MajorTopicYN="N">asunaprevir</Keyword><Keyword MajorTopicYN="N">hepatitis C</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">interferon type I</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28473813</ArticleId><ArticleId IdType="pmc">PMC5397474</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2017.00668</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bartenschlager R., Binder M., Thimme R. (2012). Failure of innate and adaptive immune response in controlling hepatitis C virus infection. FEMS Microbiol. Rev. 36, 663&#x2013;683. 10.1111/j.1574-6976.2011.00319.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2011.00319.x</ArticleId><ArticleId IdType="pubmed">22142141</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang T. H., Kubota T., Matsuoka M., Jones S., Bradfute S. B., Bray M., et al. (2009). Ebola virus VP35 blocks type I interferon transcription in dendritic cells by interacting with the cellular SUMOylation machinery. PLoS Pathog. 5:e1000493 10.1371/journal.ppat.1000493</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000493</ArticleId><ArticleId IdType="pmc">PMC2696038</ArticleId><ArticleId IdType="pubmed">19557165</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang T. H., Liao C. L., Lin Y. L. (2006). Flavivirus induced interferon-beta gene expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-dependent NF-kappaB activation. Microb. Infect. 8, 157&#x2013;171. 10.1016/j.micinf.2005.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2005.06.014</ArticleId><ArticleId IdType="pubmed">16182584</ArticleId></ArticleIdList></Reference><Reference><Citation>Chayama K., Takahashi S., Toyota J., Karino Y., Ikeda K., Ishikawa H., et al. . (2012). Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55, 742&#x2013;748. 10.1002/hep.24724</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.24724</ArticleId><ArticleId IdType="pubmed">21987462</ArticleId></ArticleIdList></Reference><Reference><Citation>Fattovich G., Stroffolini T., Zagni I., Donato F. (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(Suppl. 1), S35&#x2013;S50. 10.1053/j.gastro.2004.09.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.09.014</ArticleId><ArticleId IdType="pubmed">15508101</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusco D. N., Brisac C., John S. P., Huang Y. W., Chin C. R., Xie T., et al. . (2013). A genetic screen identifies interferon-&#x3b1; effector genes required to suppress hepatitis C virus replication. Gastroenterology 144, 1438&#x2013;1449. 10.1053/j.gastro.2013.02.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.02.026</ArticleId><ArticleId IdType="pmc">PMC3665646</ArticleId><ArticleId IdType="pubmed">23462180</ArticleId></ArticleIdList></Reference><Reference><Citation>Green A. M., Beatty P. R., Hadjilaou A., Harris E. (2012). Innate immunity evasion by Dengue virus. Viruses 4, 397&#x2013;413. 10.3390/v4030397</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v4030397</ArticleId><ArticleId IdType="pmc">PMC3347034</ArticleId><ArticleId IdType="pubmed">22590678</ArticleId></ArticleIdList></Reference><Reference><Citation>Green A. M., Beatty P. R., Hadjilaou A., Harris E. (2014). Innate immunity to dengue virus infection and subversion of antiviral responses. J. Mol. Biol. 426, 1148&#x2013;1160. 10.1016/j.jmb.2013.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2013.11.023</ArticleId><ArticleId IdType="pmc">PMC4174300</ArticleId><ArticleId IdType="pubmed">24316047</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler D. J. (1989). Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Charles Franklin Craig lecture. Am. J. Trop. Med. Hyg. 40, 571&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">2472746</ArticleId></ArticleIdList></Reference><Reference><Citation>Horner S. M., Gale M., Jr. (2013). Regulation of hepatic innate immunity by hepatitis C virus. Nat. Med. 19, 879&#x2013;888. 10.1038/nm.3253</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3253</ArticleId><ArticleId IdType="pmc">PMC4251871</ArticleId><ArticleId IdType="pubmed">23836238</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J. L., Coyne C. B. (2013). Mechanisms of MAVS regulation at the mitochondrial membrane. J. Mol. Biol. 425, 5009&#x2013;5019. 10.1016/j.jmb.2013.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2013.10.007</ArticleId><ArticleId IdType="pmc">PMC4562275</ArticleId><ArticleId IdType="pubmed">24120683</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao J. H., Chen D. S. (2005). Changing disease burden of hepatocellular carcinoma in the Far East and Souteast Asia. Liver Int. 25, 696&#x2013;703. 10.1111/j.1478-3231.2005.01139.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2005.01139.x</ArticleId><ArticleId IdType="pubmed">15998418</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Foy E., Ferreon J. C., Nakamura M., Ferreon A. C., Ikeda M., et al. . (2005). Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. U.S.A. 102, 2992&#x2013;2997. 10.1073/pnas.0408824102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0408824102</ArticleId><ArticleId IdType="pmc">PMC548795</ArticleId><ArticleId IdType="pubmed">15710891</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Li N. L., Wei D., Pfeffer S. R., Fan M., Pfeffer L. M. (2012). Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 55, 666&#x2013;675. 10.1002/hep.24763</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.24763</ArticleId><ArticleId IdType="pmc">PMC3272326</ArticleId><ArticleId IdType="pubmed">22030901</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X. D., Sun L., Seth R. B., Pineda G., Chen Z. J. (2005). Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. U.S.A. 102, 17717&#x2013;17722. 10.1073/pnas.0508531102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0508531102</ArticleId><ArticleId IdType="pmc">PMC1308909</ArticleId><ArticleId IdType="pubmed">16301520</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang T. J., Ghany M. G. (2014). Therapy of hepatitis C&#x2013;back to the future. N. Engl. J. Med. 370, 2043&#x2013;2047. 10.1056/NEJMe1403619</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe1403619</ArticleId><ArticleId IdType="pmc">PMC6324541</ArticleId><ArticleId IdType="pubmed">24795199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W., Tsai W. L., Shao R. X., Wu G., Peng L. F., Barlow L. L., et al. . (2010). Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 138, 2509&#x2013;2518. 10.1053/j.gastro.2010.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.03.008</ArticleId><ArticleId IdType="pmc">PMC2883661</ArticleId><ArticleId IdType="pubmed">20230822</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y. L., Liao C. L., Chen L. K., Yeh C. T., Liu C. I., Ma S. H., et al. (1998). Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 2, 9729&#x2013;9737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110483</ArticleId><ArticleId IdType="pubmed">9811707</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H. M., Gale M. J. (2010). Hepatitis C virus evasion from RIG-I-dependent hepatic innate immunity. Gastroenterol. Res. Pract. 8, 1&#x2013;8. 10.1155/2010/548390</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2010/548390</ArticleId><ArticleId IdType="pmc">PMC3026989</ArticleId><ArticleId IdType="pubmed">21274284</ArticleId></ArticleIdList></Reference><Reference><Citation>Manns M., Pol S., Jacobson I. M., Marcellin P., Gordon S. C., Peng C. Y., et al. . (2014). All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384, 1597&#x2013;1605. 10.1016/S0140-6736(14)61059-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61059-X</ArticleId><ArticleId IdType="pubmed">25078304</ArticleId></ArticleIdList></Reference><Reference><Citation>Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., et al. . (2005). Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167&#x2013;1172. 10.1038/nature04193</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04193</ArticleId><ArticleId IdType="pubmed">16177806</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison J., Aguirre S., Fernandez-Sesma A. (2012). Innate immunity evasion by Dengue virus. Viruses 4, 397&#x2013;413. 10.3390/v4030397</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v4030397</ArticleId><ArticleId IdType="pmc">PMC3347034</ArticleId><ArticleId IdType="pubmed">22590678</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble C. G., Chen Y. L., Dong H., Gu F., Lim S. P., Schul W., et al. . (2010). Strategies for development of Dengue virus inhibitors. Antiviral Res. 85, 450&#x2013;462. 10.1016/j.antiviral.2009.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.12.011</ArticleId><ArticleId IdType="pubmed">20060421</ArticleId></ArticleIdList></Reference><Reference><Citation>Olagnier D., Scholte F. E., Chiang C., Albulescu I. C., Nichols C., He Z., et al. . (2014). Inhibition of Dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. J. Virol. 88, 4180&#x2013;4194. 10.1128/JVI.03114-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03114-13</ArticleId><ArticleId IdType="pmc">PMC3993760</ArticleId><ArticleId IdType="pubmed">24478443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ploss A., Dubuisson J. (2012). New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 61(Suppl. 1), i25&#x2013;i35. 10.1136/gutjnl-2012-302048</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-302048</ArticleId><ArticleId IdType="pubmed">22504917</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole R. M. (2014). Daclatasvir + asunaprevir: first global approval. Drugs 74, 1559&#x2013;1571. 10.1007/s40265-014-0279-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-014-0279-4</ArticleId><ArticleId IdType="pubmed">25117197</ArticleId></ArticleIdList></Reference><Reference><Citation>Sameul C. E. (2001). Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778&#x2013;809. 10.1128/CMR.14.4.778-809.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.14.4.778-809.2001</ArticleId><ArticleId IdType="pmc">PMC89003</ArticleId><ArticleId IdType="pubmed">11585785</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer E. A., Chung R. T. (2012). Anti-hepatitis C virus drugs in development. Gastroenterology 142, 1340&#x2013;1350.e1. 10.1053/j.gastro.2012.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2012.02.015</ArticleId><ArticleId IdType="pubmed">22537441</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler C., Plumlee C. (2008). Interferons and the JAK-STAT pathway. Semin. Cell Dev. Biol. 19, 311&#x2013;318. 10.1016/j.semcdb.2008.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2741134</ArticleId><ArticleId IdType="pubmed">18765289</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins J. W., Rice C. M. (2011). Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1, 519&#x2013;525. 10.1016/j.coviro.2011.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2011.10.008</ArticleId><ArticleId IdType="pmc">PMC3274382</ArticleId><ArticleId IdType="pubmed">22328912</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins J. W., Wilson S. J., Panis M., Murphy M. Y., Jones C. T., Bieniasz P., et al. . (2011). A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481&#x2013;485. 10.1038/nature09907</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09907</ArticleId><ArticleId IdType="pmc">PMC3409588</ArticleId><ArticleId IdType="pubmed">21478870</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W. A., Chung R. T. (2009). Treatment failure in hepatitis C: mechanisms of non-response. J. Hepatol. 50, 412&#x2013;420. 10.1016/j.jhep.2008.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2008.11.010</ArticleId><ArticleId IdType="pmc">PMC2743341</ArticleId><ArticleId IdType="pubmed">19070928</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughn D. W., Green S., Kalayanarooj S., Innis B. L., Nimmannitya S., Suntayakorn S., et al. . (2000). Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181, 2&#x2013;9. 10.1086/315215</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315215</ArticleId><ArticleId IdType="pubmed">10608744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L. F., Lin Y. S., Huang N. C., Yu C. Y., Tsai W. L., Chen J. J., et al. . (2014). Hydroxychloroquine-Inhibited Dengue Virus Is associated with host defense machinery. J. Interferon Cytokine Res. 35, 143&#x2013;156. 10.1089/jir.2014.0038</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2014.0038</ArticleId><ArticleId IdType="pmc">PMC4350140</ArticleId><ArticleId IdType="pubmed">25321315</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N., Liang Y., Devaraj S., Wang J., Lemon S. M., Li K. (2009). Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J. Virol. 83, 9824&#x2013;9834. 10.1128/JVI.01125-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01125-09</ArticleId><ArticleId IdType="pmc">PMC2747996</ArticleId><ArticleId IdType="pubmed">19625408</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO (2009). World Health Organization Geneva Switzerland and World Health Organization Dengue: Guidelines for Diagnosis, Treatment, Prevention, and Control. Geneva: World Health Organization.</Citation></Reference><Reference><Citation>WHO (2012). World Health Organization Geneva Switzerland and World Health Organization Dengue and Severe Dengue. Geneva: World Health Organization.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>